Fed’s Powell opens door to potential rate cuts at Jackson Hole
Daniel J. Moorhead, the Chief Financial Officer of Zynex Inc. (NASDAQ:ZYXI), a medical technology company with a market capitalization of $231 million, recently sold a portion of his holdings in the company. According to a recent SEC filing, Moorhead sold 10,000 shares of Zynex common stock on March 3, 2025, at an average price of $7.15 per share, amounting to a total transaction value of $71,500. The stock price, currently trading near its 52-week low of $7.01, suggests challenging market conditions. This transaction was conducted under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for selling stocks.
Additionally, on March 5, 2025, Zynex withheld 4,530 shares from Moorhead to satisfy tax obligations related to restricted stock awards, valued at $32,751 based on a price of $7.23 per share. This withholding does not constitute a sale.
On the same day, Moorhead received a restricted stock award of 5,000 shares as part of Zynex’s 2017 Stock Incentive Plan. These shares will vest equally over four years, starting one year from the grant date.
Following these transactions, Moorhead holds 68,855 shares of Zynex stock.
In other recent news, Zynex, Inc. has announced a partnership with Veterans Affairs Medical (TASE:BLWV) Centers across the United States. This collaboration is intended to expand Zynex’s reach in the VA’s healthcare system, which serves over 9 million veterans. The partnership is expected to enhance the company’s market presence, as its current sales within the VAMCs represent less than 1% of its total revenue. Additionally, H.C. Wainwright maintained a Buy rating for Zynex’s stock, following the company’s progress with its NiCO pulse oximeter at Duke University. The device is in the final testing phase before an anticipated 510(k) application submission, which could occur later this month or in early 2025. The NiCO pulse oximeter is noted for its advanced monitoring capabilities, potentially positioning Zynex to penetrate the multi-billion dollar pulse oximetry market. The analyst firm highlighted the potential for FDA clearance by mid-2025, which would mark a significant milestone for Zynex. These developments reflect a period of strategic growth and innovation for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.